首页 > 市场调查报告书 > 製药

医药品法规环境

市场调查报告书

商品编码

1986467

药品安全监测和药品安全软体市场报告：按功能、交付方式、最终用户和地区划分（2026-2034 年）

Pharmacovigilance and Drug Safety Software Market Report by Functionality, Delivery Mode, End User, and Region 2026-2034

出版日期: 2026年03月01日 | 出版商:

IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

2025年，全球药品安全监测和药品安全软体市场规模达2.262亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到3.617亿美元，2026年至2034年的复合年增长率（CAGR）为5.19%。推动市场成长的主要因素包括：慢性病在人群中的日益普遍、药品销售监管的日益严格，以及软体功能和使用者友善介面的不断进步。

药物警戒和药物警戒软体是指专门设计的电脑程序，旨在简化和加强对不利事件（ADR）及其他药物相关安全问题的监测、分析和报告。这些软体系统在药物警戒领域中发挥着至关重要的作用，药物警戒致力于确保药物的安全有效使用。这些软体解决方案使製药公司、监管机构和医疗保健专业人员能够有效率地收集、管理和分析大量的药物安全资料。它们还有助于发现潜在风险和模式，从而实现及时干预和风险缓解策略。

药物警戒和药物安全软体市场的发展主要得益于临床研究机构和外包公司对这类软体解决方案的日益普及。这些机构认识到，健全的药物警戒系统对于确保在开发药物和上市后监测药物的安全性和有效性至关重要。此外，慢性病盛行率的上升也促进了市场成长。随着需要长期用药的患者数量增加，对有效药物安全监测和管理的需求也日益增长。同时，由于世界各国政府对药物商业化实施了严格的监管，药物安全法规的复杂性也随之增加，进一步刺激了市场需求。此外，最尖端科技技术的普及也使得药物安全检测和药物安全软体的实施更加便捷。软体功能的不断发展和用户友好介面的日益完善，也使得各机构能够轻鬆地将这些解决方案部署并整合到现有工作流程中，从而对市场产生积极影响。

药物安全检测和药物安全软体市场的趋势和驱动因素：

製药业的扩张

製药业的蓬勃发展对全球药物安全检测（PV）和药物安全软体市场产生了显着影响。随着製药业的扩张，新药和新疗法的研发日益增加。这推动了对药物警戒和药物安全软体的需求，使其能够监测、分析和管理不利事件，从而带动了此类软体需求的成长。此外，製药业的扩张也增加了数据量和数据的复杂性，需要先进的软体来管理和分析这些数据。这促使人工智慧和机器学习技术在药物警戒和药物安全软体中开发和应用，以有效处理此类复杂的数据集。此外，药物安全检测和药物安全软体也支援风险管理需求，而日益增长的风险管理需求也推动了该市场的发展。

不利事件发生率增加

不利事件（ADR）发生率的不断上升正对全球药物警戒和药物安全软体市场产生重大影响。报告的不良药物事件数量的增加，推动了对强大的药物警戒系统和软体解决方案的需求日益增长，以确保上市药物的安全性和有效性。不利事件可能对患者的健康和福祉造成严重后果，甚至导致住院、额外的医疗费用，甚至死亡。因此，世界各地的监管机构正在实施严格的指导方针和法规，以确保製药公司能够有效监测和报告不良药物事件。因此，全球药物安全检测和药物安全软体市场正经历显着成长，这正是对不良药物事件发生率上升的直接回应。这是因为提供这些软体解决方案的公司不断创新，提供能够有效处理大量不利事件资料的先进工具和功能。

医疗保健支出不断增加

随着全球医疗保健支出持续成长，优化病人安全和提升整体医疗服务品质的重要性日益凸显。药物安全检测和药物安全软体在实现这些目标中发挥着至关重要的作用，它们能够有效监测、评估和管理不利事件（ADR）及其他药物相关问题。随着医疗保健支出的增加，对病人安全的关注度也随之提升。药物安全检测软体为医疗机构和监管机构提供监测和预防药物不良事件的工具，从而减轻与药物相关不利事件相关的经济负担。此外，随着医疗保健成本的不断攀升，资源优化至关重要。药物安全检测软体还能有效管理不利事件数据，并简化通报和分析流程。

The global pharmacovigilance and drug safety software market size reached USD 226.2 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 361.7 Million by 2034, exhibiting a growth rate (CAGR) of 5.19% during 2026-2034. The growing prevalence of chronic diseases among the masses, the implementation of strict regulations on the commercialization of drugs, and continual advancements in software capabilities and user-friendly interfaces are some of the major factors propelling the market.

Pharmacovigilance and drug safety software refers to specialized computer programs designed to streamline and enhance the monitoring, analysis, and reporting of adverse drug reactions (ADRs) and other drug-related safety concerns. These software systems play a crucial role in the field of pharmacovigilance, which is dedicated to ensuring the safe and effective use of medications. These software solutions enable pharmaceutical companies, regulatory authorities, and healthcare professionals to efficiently collect, manage, and analyze large volumes of data pertaining to drug safety. They also facilitate the detection of potential risks and patterns, allowing for timely intervention and risk mitigation strategies.

The pharmacovigilance and drug safety software market is driven by the increasing adoption of these software solutions by clinical research and outsourcing companies. These organizations recognize the importance of robust pharmacovigilance systems to ensure the safety and efficacy of drugs in development and post-marketing surveillance. Moreover, the growing prevalence of chronic diseases is also contributing to the growth of the market. As the number of patients requiring long-term medication increases, so does the need for effective drug safety monitoring and management. Apart from this, governments worldwide are imposing strict regulations on the commercialization of drugs, leading to increased complexity in drug safety regulations, further impelling the demand. Besides, the availability of cutting-edge technology is facilitating the easy adoption of pharmacovigilance and drug safety software. Furthermore, continual advancements in software capabilities and user-friendly interfaces make it easier for organizations to implement and integrate these solutions into their existing workflows, thus impacting the market favorably.

PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE MARKET TRENDS/DRIVERS:

Expansion of the Pharmaceutical Industry

The development of the pharmaceutical industry is having a significant influence on the global pharmacovigilance (PV) and drug safety software market. As the pharmaceutical industry expands, there has been an increase in the development of new drugs and therapies. This leads to a greater need for PV and drug safety software to monitor, analyze, and manage adverse events, leading to an increase in demand for this software. Moreover, the pharmaceutical industry's expansion has led to a rise in data volume and complexity, requiring sophisticated software for managing and analyzing data. This is driving the development and adoption of AI and machine learning within PV and drug safety software to handle, such complex datasets effectively. Also, pharmacovigilance and drug safety software help manage these risks, and the growing need for risk management is driving demand in this market.

Growing Incidence of Adverse Drug Reactions

The increasing incidence of adverse drug reactions (ADRs) is significantly influencing the global pharmacovigilance and drug safety software market. The raising number of reported ADRs has created a greater need for robust pharmacovigilance systems and software solutions to ensure the safety and efficacy of drugs in the market. Adverse drug reactions can have serious consequences on patient health and well-being, leading to hospitalizations, additional medical costs, and even fatalities. Therefore, regulatory authorities worldwide have implemented stringent guidelines and regulations for pharmaceutical companies to monitor and report ADRs effectively. Along with this, the global pharmacovigilance and drug safety software market has experienced significant growth as a direct response to the rising incidence of ADRs since companies offering these software solutions are continuously innovating to provide advanced tools and functionalities that can handle large volumes of adverse event data efficiently.

The Increasing Healthcare Expenditure

As healthcare expenditure continues to rise globally, there is a growing emphasis on optimizing patient safety and improving the overall quality of healthcare delivery. Pharmacovigilance and drug safety software play a crucial role in achieving these objectives by ensuring the effective monitoring, assessment, and management of adverse drug reactions (ADRs) and other drug-related problems. With higher healthcare spending, there has been a growing focus on patient safety. Pharmacovigilance software provides healthcare organizations and regulatory authorities with the tools to monitor and prevent ADRs, thereby reducing the economic burden associated with medication-related harm. Moreover, healthcare expenditure growth necessitates the optimization of resources. Furthermore, pharmacovigilance software enables the efficient management of adverse event data, streamlining the reporting and analysis processes.

PHARMACOVIGILANCE AND DRUG SAFETY SOFTWARE INDUSTRY SEGMENTATION:

Breakup by Functionality:

Adverse Event Reporting Software
Drug Safety Audits Software
Issue Tracking Software
Fully Integrated Software

Adverse event reporting software dominates the market

Adverse event reporting software dominates the market as it is a critical aspect of regulatory compliance in the healthcare and pharmaceutical industries. It offers robust data management capabilities, allowing efficient collection, organization, and analysis of adverse event data. It enables the identification of patterns, trends, and potential safety issues associated with specific products or interventions. This data-driven approach helps pharmaceutical companies, healthcare providers, and regulatory agencies make informed decisions regarding product safety and risk mitigation strategies. Additionally, it provides a systematic and standardized approach to capturing and reporting these events, ensuring compliance with regulatory requirements. It provides a centralized platform for healthcare professionals, drug safety experts, and other stakeholders involved in adverse event reporting. Additionally, the software can scale to handle large volumes of adverse event data, ensuring its effectiveness even for organizations with extensive reporting requirements.

Breakup by Delivery Mode:

On-premises
Cloud-based

On- premises delivery holds the largest share in the market

On-premises deployment holds the largest share of the market as it provides organizations with a higher level of control and security over their data. It offers greater flexibility for customization and integration with existing systems. Organizations can tailor the software to their specific requirements and integrate it seamlessly with other on-premises applications or infrastructure. This level of customization and integration is beneficial for organizations with complex IT environments or unique business processes. The deployment allows organizations to maintain data sovereignty by ensuring that sensitive data remains within the borders of their own country. Moreover, the widespread adoption of on-premises software help eliminate the potential performance issues related to network latency or dependence on internet connectivity. Also, it allows organizations to maintain compliance and meet regulatory standards more easily.

Breakup by End User:

Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Business Process Outsourcing Firms
Others

Contract research organizations hold the largest share in the market

CROs hold a significant position and are the leading users of the market's products or services. They specialize in providing comprehensive research services, allowing pharmaceutical and biotech companies to outsource various aspects of their R&D activities. This outsourcing model offers numerous benefits, including access to specialized expertise, reduced operational costs, and increased efficiency in trial execution. They provide in-depth knowledge of industry best practices, regulatory requirements, and emerging trends which makes it an attractive choice for companies seeking reliable partners to navigate complex research processes and achieve successful outcomes. They also have the ability to scale their resources and infrastructure according to project requirements, enabling them to support both small-scale studies and large multinational trials. They can provide expertise in risk management, data integrity, and compliance, helping companies navigate the complex regulatory landscape and mitigate potential pitfalls.

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

North America exhibits a clear dominance, accounting for the largest pharmacovigilance and drug safety software market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a robust and well-established pharmaceutical industry, with numerous companies involved in drug discovery, development, and commercialization. The region is at the forefront of technological innovation, including advancements in healthcare and information technology. The region has a robust IT infrastructure, a favorable investment climate for research and development, and a strong focus on adopting digital solutions. North American pharmaceutical companies and research institutions often collaborate with academic institutions, healthcare providers, and technology companies to drive innovation in pharmacovigilance and drug safety. These collaborations foster the development and adoption of state-of-the-art software solutions, further enhancing North America's dominance in the market. Additionally, the region has stringent regulatory requirements for drug safety and pharmacovigilance is another significant factor responsible for impelling the market across the North America region.

COMPETITIVE LANDSCAPE:

Top companies in the market are investing in research and development activities to create advanced pharmacovigilance and drug safety software solutions. These software platforms are designed to capture, process, analyze, and report adverse events, safety data, and other relevant information related to pharmaceutical products and medical interventions. Various companies offer flexible and scalable software platforms that can be tailored to meet the unique needs of pharmaceutical companies, CROs, and healthcare institutions. Additionally, companies leverage advanced data analytics techniques, such as artificial intelligence (AI) and machine learning (ML), to analyze large volumes of safety data and identify potential safety signals. These analytics capabilities help in the early detection of adverse events, signal management, risk assessment, and trend analysis.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AB Cube S.A.S.
Anju Software
ArisGlobal
Ennov
Extedo
Honeywell International Inc.
IQVIA Inc.
Oracle
Sarjen Systems Pvt. Ltd.
United BioSource LLC
Veeva Systems Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global pharmacovigilance and drug safety software market in 2025?

2. What is the expected growth rate of the global pharmacovigilance and drug safety software market during 2026-2034?

3. What has been the impact of COVID-19 on the global pharmacovigilance and drug safety software market?

4. What are the key factors driving the global pharmacovigilance and drug safety software market?

5. What is the breakup of the global pharmacovigilance and drug safety software market based on the functionality?

6. What is the breakup of the global pharmacovigilance and drug safety software market based on the delivery mode?

7. What is the breakup of the global pharmacovigilance and drug safety software market based on the end user?

8. What are the key regions in the global pharmacovigilance and drug safety software market?

9. Who are the key players/companies in the global pharmacovigilance and drug safety software market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Pharmacovigilance and Drug Safety Software Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Functionality

6.1 Adverse Event Reporting Software
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Drug Safety Audits Software
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Issue Tracking Software
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Fully Integrated Software
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Delivery Mode

7.1 On-premises
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Cloud-based
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Contract Research Organizations
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Business Process Outsourcing Firms
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 AB Cube S.A.S.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
- 14.3.2 Anju Software
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
- 14.3.3 ArisGlobal
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
- 14.3.4 Ennov
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
- 14.3.5 Extedo
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
- 14.3.6 Honeywell International Inc.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
- 14.3.7 IQVIA Inc.
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Oracle
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Sarjen Systems Pvt. Ltd.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
- 14.3.10 United BioSource LLC
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
- 14.3.11 Veeva Systems Inc.
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
  - 14.3.11.4 SWOT Analysis

简介目录图表

List of Figures

Figure 1: Global: Pharmacovigilance and Drug Safety Software Market: Major Drivers and Challenges
Figure 2: Global: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020-2025
Figure 3: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 4: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by Functionality (in %), 2025
Figure 5: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by Delivery Mode (in %), 2025
Figure 6: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by End User (in %), 2025
Figure 7: Global: Pharmacovigilance and Drug Safety Software Market: Breakup by Region (in %), 2025
Figure 8: Global: Pharmacovigilance and Drug Safety Software (Adverse Event Reporting Software) Market: Sales Value (in Million USD), 2020 & 2025
Figure 9: Global: Pharmacovigilance and Drug Safety Software (Adverse Event Reporting Software) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 10: Global: Pharmacovigilance and Drug Safety Software (Drug Safety Audits Software) Market: Sales Value (in Million USD), 2020 & 2025
Figure 11: Global: Pharmacovigilance and Drug Safety Software (Drug Safety Audits Software) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 12: Global: Pharmacovigilance and Drug Safety Software (Issue Tracking Software) Market: Sales Value (in Million USD), 2020 & 2025
Figure 13: Global: Pharmacovigilance and Drug Safety Software (Issue Tracking Software) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 14: Global: Pharmacovigilance and Drug Safety Software (Fully Integrated Software) Market: Sales Value (in Million USD), 2020 & 2025
Figure 15: Global: Pharmacovigilance and Drug Safety Software (Fully Integrated Software) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 16: Global: Pharmacovigilance and Drug Safety Software (On-premises) Market: Sales Value (in Million USD), 2020 & 2025
Figure 17: Global: Pharmacovigilance and Drug Safety Software (On-premises) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 18: Global: Pharmacovigilance and Drug Safety Software (Cloud-based) Market: Sales Value (in Million USD), 2020 & 2025
Figure 19: Global: Pharmacovigilance and Drug Safety Software (Cloud-based) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 20: Global: Pharmacovigilance and Drug Safety Software (Pharmaceutical and Biotechnology Companies) Market: Sales Value (in Million USD), 2020 & 2025
Figure 21: Global: Pharmacovigilance and Drug Safety Software (Pharmaceutical and Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 22: Global: Pharmacovigilance and Drug Safety Software (Contract Research Organizations) Market: Sales Value (in Million USD), 2020 & 2025
Figure 23: Global: Pharmacovigilance and Drug Safety Software (Contract Research Organizations) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 24: Global: Pharmacovigilance and Drug Safety Software (Business Process Outsourcing Firms) Market: Sales Value (in Million USD), 2020 & 2025
Figure 25: Global: Pharmacovigilance and Drug Safety Software (Business Process Outsourcing Firms) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 26: Global: Pharmacovigilance and Drug Safety Software (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
Figure 27: Global: Pharmacovigilance and Drug Safety Software (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 28: North America: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 29: North America: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 30: United States: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 31: United States: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 32: Canada: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 33: Canada: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 34: Asia-Pacific: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 35: Asia-Pacific: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 36: China: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 37: China: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 38: Japan: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 39: Japan: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 40: India: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 41: India: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 42: South Korea: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 43: South Korea: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 44: Australia: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 45: Australia: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 46: Indonesia: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 47: Indonesia: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 48: Others: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 49: Others: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 50: Europe: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 51: Europe: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 52: Germany: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 53: Germany: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 54: France: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 55: France: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 56: United Kingdom: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 57: United Kingdom: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 58: Italy: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 59: Italy: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 60: Spain: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 61: Spain: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 62: Russia: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 63: Russia: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 64: Others: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 65: Others: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 66: Latin America: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 67: Latin America: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 68: Brazil: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 69: Brazil: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 70: Mexico: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 71: Mexico: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 72: Others: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 73: Others: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 74: Middle East and Africa: Pharmacovigilance and Drug Safety Software Market: Sales Value (in Million USD), 2020 & 2025
Figure 75: Middle East and Africa: Pharmacovigilance and Drug Safety Software Market: Breakup by Country (in %), 2025
Figure 76: Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 77: Global: Pharmacovigilance and Drug Safety Software Industry: SWOT Analysis
Figure 78: Global: Pharmacovigilance and Drug Safety Software Industry: Value Chain Analysis
Figure 79: Global: Pharmacovigilance and Drug Safety Software Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Pharmacovigilance and Drug Safety Software Market: Key Industry Highlights, 2025 and 2034
Table 2: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by Functionality (in Million USD), 2026-2034
Table 3: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by Delivery Mode (in Million USD), 2026-2034
Table 4: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by End User (in Million USD), 2026-2034
Table 5: Global: Pharmacovigilance and Drug Safety Software Market Forecast: Breakup by Region (in Million USD), 2026-2034
Table 6: Global: Pharmacovigilance and Drug Safety Software Market: Competitive Structure
Table 7: Global: Pharmacovigilance and Drug Safety Software Market: Key Players

02-2729-4219

+886-2-2729-4219

License/价格

药品安全监测和药品安全软体市场报告：按功能、交付方式、最终用户和地区划分（2026-2034 年）

Pharmacovigilance and Drug Safety Software Market Report by Functionality, Delivery Mode, End User, and Region 2026-2034

药物安全检测和药物安全软体市场的趋势和驱动因素：

目录

第一章：序言

第二章：调查方法

第三章执行摘要

第四章：引言

第五章：全球药品安全监测与药品安全软体市场

第六章 市场区隔：依功能划分

第七章 市场区隔：依交付方式划分

第八章 市场区隔：依最终用户划分

第九章 市场区隔：依地区划分

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

第十四章 竞争格局